The number of people with chronic conditions is increasing worldwide. In this context, the demand for Ypsomed’s autoinjectors and pens is growing rapidly, as they en...

Use of Contract Development Manufacturing Organisations (CDMOs) is now the established norm in the pharmaceutical and medical technology supply chain. The CDMO model...

The pharmaceutical industry and the creation of new drugs is expected to continue growing at a steady rate over the next decade. To keep up with this growth, many co...

Recent medicine shortages across Europe have highlighted critical gaps in the resilience and security of our healthcare systems, prompting decisive action from the E...

In this article, Vincenza Pironti, Head of Business Development at Recipharm, explores the latest trends in messenger RNA (mRNA) drug development, dives into the dev...

Even after decades of research and everincreasing R&D spending, the overall success rate of oncology programmes remains low. At an industry level, over $50bn is ...

Inflammatory bowel disease (IBD) is a term for two conditions (Crohn's Disease and Ulcerative Colitis) that are characterised by chronic inflammation of the gastroin...

The increasing global incidence of cancer underscores the urgent need for more effective and targeted treatments. Highly potent active pharmaceutical ingredients (HP...

With autoimmune diseases cumulatively affecting 5 to 10% of the industrial world population, the global market for autoimmune therapeutics is set to grow at a CAGR o...

Complex drug formulations, stringent regulatory standards, and a tough capital landscape are creating pressure for drug developers as they approach clinical trials. ...